Anticoagulation and bleeding: A pooled analysis of lung cancer trials of the ncic clinical trials group

Journal of Thoracic Oncology

Volumn 4, Issue 5, 2009, Pages 586-594

  Maître, Aurélie Le ^a   Ding, Keyue ^a   Shepherd, Frances A ^b   Leighl, Natasha ^b   Arnold, Andrew ^c   Seymour, Lesley ^a  

^a QUEEN S UNIVERSITY   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c JURAVINSKI CANCER CENTRE   (Canada)

Author keywords

Anticoagulation; Bleeding; Lung cancer

Indexed keywords

CARBOPLATIN; ERLOTINIB; LOW MOLECULAR WEIGHT HEPARIN; PACLITAXEL; PLACEBO; REBIMASTAT; VANDETANIB; WARFARIN; ANTICOAGULANT AGENT; ANTINEOPLASTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; AGED; ANTICOAGULATION; ARTICLE; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT OUTCOME; CHEMICALLY INDUCED DISORDER; LUNG DISEASE; LUNG TUMOR; META ANALYSIS; PROGNOSIS; RETROSPECTIVE STUDY; RISK FACTOR; VENOUS THROMBOEMBOLISM;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTICOAGULANTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HEMORRHAGE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; LUNG DISEASES; LUNG NEOPLASMS; MALE; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; RISK FACTORS; VENOUS THROMBOEMBOLISM; WARFARIN;

EID: 67651159242     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e31819f9a8a     Document Type: Article

References (14)

1. Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 2005; 293:715-722. (Pubitemid 40216041)
2. Stein PD, Beemath A, Meyers FA, Skaf E, Sanchez J, Olson RE. Incidence of venous thromboembolism in patients hospitalized with cancer. Am J Med 2006;119:60-68. (Pubitemid 43117468)
3. Chew HK, Davies AM, Wun T, Harvey D, Zhou H, White RH. The incidence of venous thromboembolism among patients with primary lung cancer. J Thromb Haemost 2008;6:601-608.
4. Shepherd F, Hasan B, Hicks L, et al. Venous thromboembolism and non-small cell lung cancer: a pooled analysis of National Cancer Institute of Canada Clinical Trials Group trials. Eur J Caner 2007;5(Suppl): 361.
5. Hutten BA, Prins MH, Gent M, Ginsberg J, Tijssen JG, Büller HR. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol 2000;18:3078-3083. (Pubitemid 30677087)
6. Prandoni P, Lensing A, Piccioli A, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002;100:3484-3488. (Pubitemid 35303914)
7. Iorio A, Guercini F, Pini M. Low-molecular-weight heparin for the long-term treatment of symptomatic venous thromboembolism: meta analysis of the randomized comparisons with oral anticoagulants. J Thromb Haemost 2003;1:1906-1913.
8. Akl E, Barba M, Rohilla S, et al. Low-molecular-weight heparins are superior to vitamin K antagonists for the long term treatment of venous thromboembolism in patients with cancer: a cochrane systematic review. J Exp Clin Cancer Res [serial online] 2008;27:21. Available from: www.jeccr.com. Accessed August 15, 2008.
9. Meyer G, Marjanovic Z, Valcke J, et al. Comparison of low molecularweight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer. Arch Int Med 2002;162: 1729-1735. (Pubitemid 34894802)
10. Lee AYY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. New Engl J Med 2003;349:146-153. (Pubitemid 36818784)
11. Leighl NB, Paz-Ares L, Douillard JY, et al. Randomized phase III study of matrix metalloproteinase inhibitor BMS-275291 in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR. 18. J Clin Oncol 2005;23:2831-2839.
12. Arnold AM, Seymour L, Smylie M, et al. Phase II study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy: National Cancer Institute of Canada Clinical Trials Group Study BR. 20. J Clin Oncol 2007;25:4278-4284. (Pubitemid 47548568)
13. Shepherd FA, Pereira JR, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-132. (Pubitemid 41058344)
14. Crabb SJ, Patsios D, Sauerbrei E, et al. Tumor cavitation: impact on objective response evaluation in trials of angiogenesis inhibitors in non-small cell lung cancer. J Clin Oncol 2009;27:404-410